Unraveling pacemaker (dys)function using novel stem cell-derived human heart models
This project aims to enhance understanding of sinoatrial node function and its dysfunction in heart rhythm disorders using innovative in vitro models derived from human pluripotent stem cells.
Projectdetails
Introduction
The pacemaker cells of the sinoatrial node (SAN) trigger three billion heartbeats in an average human lifespan. At the start of each beat, the SAN must generate enough current to drive the surrounding atrial tissue, which contains 10,000 times as many cells as the SAN itself.
Biological Mechanisms
This extraordinary biological feat is a result of intrinsic features such as SAN tissue architecture. In addition, SAN function is modulated by extrinsic inputs from the autonomic nervous system, which adjusts the pace from beat-to-beat, for example during exercise.
SAN Dysfunction
Any disturbances to these core activities result in SAN dysfunction, which includes:
- Abnormal heart rate (brady or tachycardias)
- SAN exit block (lack of atrial activation)
- Chronotropic incompetence (inability to increase heart rate)
SAN dysfunction is also a major trigger for atrial fibrillation, the most common form of arrhythmia.
Research Goals
The goal of this ERC-StG proposal is to make significant leaps in our understanding of the intrinsic and extrinsic factors that regulate SAN function in health and disease using innovative multi-cell type as well as multi-organ in vitro models created from human pluripotent stem cells.
Objectives
-
Role of SAN Subpopulations: Determine the role of SAN subpopulations, particularly transitional cells, in facilitating impulse propagation at the pacemaker-atrial interface by evaluating an SCN5A loss-of-function mutation.
-
Insights into SAN Dysfunction and Atrial Fibrillation: Gain insights into the relationship between SAN dysfunction and atrial fibrillation by assessing MYH6 variants associated with both these diseases.
-
Impact of Neurodegenerative Diseases: Unravel how damage to autonomic function in the higher orders of the brain, for example, in neurodegenerative diseases such as Huntington’s, disrupts the electrical activity of pacemaker cells.
Conclusion
This research will provide exquisite knowledge of the fundamental principles that regulate pacemaker function, which is essential to effectively address SAN dysfunction and atrial arrhythmias.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.797.105 |
Totale projectbegroting | € 1.797.105 |
Tijdlijn
Startdatum | 1-5-2024 |
Einddatum | 30-4-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- STICHTING AMSTERDAM UMCpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Advanced human models of the heart to understand cardiovascular diseaseHeart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Translational optoelectronic control of cardiac rhythm in atrial fibrillationThis project aims to develop a shock-free, optoelectronic method for controlling cardiac rhythm in atrial fibrillation using engineered 3D heart models and advanced monitoring systems. | ERC Consolid... | € 1.999.999 | 2023 | Details |
Programming the EPIcardium to CURE broken heartsEPICURE aims to decode human epicardial development and regeneration using pluripotent stem cell-derived epicardioids, enhancing insights for cardiac repair through advanced imaging and CRISPR techniques. | ERC Advanced... | € 2.499.999 | 2024 | Details |
Unique non-invasive pace-mapping system to identify subjects at risk of arrhythmic sudden deathDevelop a non-invasive mapping and pacing system to detect cardiac signals for predicting sudden cardiac death, improving early diagnosis and management of heart disease. | ERC Advanced... | € 2.488.400 | 2022 | Details |
Harnessing Novel Micropeptides in Cardiomyocytes to promote Cardiac RegenerationNovel.CaRe aims to enhance cardiac regeneration post-myocardial infarction by using micropeptides to stimulate cardiomyocyte proliferation and maturation through innovative gene therapy approaches. | ERC Starting... | € 1.592.281 | 2024 | Details |
Advanced human models of the heart to understand cardiovascular disease
Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.
Translational optoelectronic control of cardiac rhythm in atrial fibrillation
This project aims to develop a shock-free, optoelectronic method for controlling cardiac rhythm in atrial fibrillation using engineered 3D heart models and advanced monitoring systems.
Programming the EPIcardium to CURE broken hearts
EPICURE aims to decode human epicardial development and regeneration using pluripotent stem cell-derived epicardioids, enhancing insights for cardiac repair through advanced imaging and CRISPR techniques.
Unique non-invasive pace-mapping system to identify subjects at risk of arrhythmic sudden death
Develop a non-invasive mapping and pacing system to detect cardiac signals for predicting sudden cardiac death, improving early diagnosis and management of heart disease.
Harnessing Novel Micropeptides in Cardiomyocytes to promote Cardiac Regeneration
Novel.CaRe aims to enhance cardiac regeneration post-myocardial infarction by using micropeptides to stimulate cardiomyocyte proliferation and maturation through innovative gene therapy approaches.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
NaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic diseases at Risk of suddEn DeathThe NaV1.5-CARED consortium aims to develop innovative therapies for cardiac arrhythmias by identifying genetic factors and therapeutic targets to restore NaV1.5 function and personalize risk assessment. | EIC Pathfinder | € 4.546.205 | 2023 | Details |
Engineering a living human Mini-heart and a swimming Bio-robotThe project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease. | EIC Pathfinder | € 4.475.946 | 2022 | Details |
Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatmentThe project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies. | EIC Pathfinder | € 3.740.868 | 2023 | Details |
NaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic diseases at Risk of suddEn Death
The NaV1.5-CARED consortium aims to develop innovative therapies for cardiac arrhythmias by identifying genetic factors and therapeutic targets to restore NaV1.5 function and personalize risk assessment.
Engineering a living human Mini-heart and a swimming Bio-robot
The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.
Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment
The project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies.